Previous in vivo studies have demonstrated that inhibition of ASK1 can effectively reduce liver and kidney injury and fibrosis and may be a possible therapeutic target for non-alcoholic steatohepatitis (NASH) and diabetic kidney disease (DKD) [52]. The gene discussed is MAP3K5; the disease is diabetic kidney disease.